Cancer cell targeting using nanoparticles
The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
1. A stealth nanoparticle having a diameter of 80 nm to 200 nm, comprising a diblock copolymer of poly (ethylene glycol) and poly (lactic) acid (PLA) or poly (ethylene glycol) and poly (lactic acid-co-glycolic) acid (PLGA);
a prostate specific membrane antigen ligand conjugate comprising by:
wherein R 1 and R 3 are alkyl groups, R 2 is an ester or amide linkage, x+y=20 to 1720, and z=25 to 455; and
a therapeutic agent wherein the nanoparticle comprises an amount of the prostate specific membrane antigen ligand conjugate that is effective for the treatment of solid tumors expressing prostate specific membrane antigen in the tumor neovasculature when the nanoparticle is intravenously administered to the patient in need thereof.
2. The nanoparticle of claim 1 , wherein the nanoparticle further comprises a polymer selected from the group consisting of PLGA or PLA.
3. The nanoparticle of claim 1 , wherein the therapeutic agent is docetaxel.
4. The nanoparticle of claim 1 , wherein y is 0.